Get the Stockscreener App
3.12
1.96%
0.06
After Hours:
3.15
0.03
+0.96%
Lixte Biotechnology Holdings Inc stock is traded at $3.12, with a volume of 83,090.
It is up +1.96% in the last 24 hours and down -8.24% over the past month.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
See More
Previous Close:
$3.06
Open:
$2.96
24h Volume:
83,090
Relative Volume:
0.91
Market Cap:
$27.15M
Revenue:
-
Net Income/Loss:
$-4.08M
P/E Ratio:
-2.6533
EPS:
-1.1759
Net Cash Flow:
$-2.58M
1W Performance:
+3.31%
1M Performance:
-8.24%
6M Performance:
-35.67%
1Y Performance:
+83.53%
1-Day Range:
$2.96
$3.2399
1-Week Range:
$2.45
$3.2399
52-Week Range:
$0.64
$6.26
Lixte Biotechnology Holdings Inc Stock (LIXT) Company Profile
Name
Lixte Biotechnology Holdings Inc
Sector
Industry
Phone
310 203 2902
Address
433 PLAZA REAL, BOCA RATON
Compare LIXT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LIXT
Lixte Biotechnology Holdings Inc
|
3.12 | 26.63M | 0 | -4.08M | -2.58M | -1.1759 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Lixte Biotechnology Holdings Inc Stock (LIXT) Latest News
LIXTE Biotechnology (LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy - NewMediaWire
LIXTE Biotechnology (NASDAQ: LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy - Digital Journal
LIXTE Biotechnology (LIXT) Aligns Liora and LiGHT System With LB-100 to Push Frontier of Cancer Treatment - NewMediaWire
LIXTE Biotechnology (NASDAQ: LIXT) Aligns Liora and LiGHT System With LB-100 to Push Frontier of Cancer Treatment - Digital Journal
LIXTE Biotechnology (LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment - Yahoo Finance
LIXTE Biotechnology (NASDAQ: LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment - Digital Journal
Earnings Miss: Will Lixte Biotechnology Holdings Inc Equity Warrant stock benefit from M AMarket Activity Report & High Accuracy Investment Entry Signals - baoquankhu1.vn
Ideas Watch: What is the next catalyst for Lixte Biotechnology Holdings Inc Equity WarrantTake Profit & Stepwise Trade Signal Implementation - baoquankhu1.vn
Improving the Odds: How LIXTE Biotechnology (NASDAQ: LIXT) Is Working to Make Cancer Therapies More Effective - The Globe and Mail
Earnings Miss: Is Lixte Biotechnology Holdings Inc stock forming a triangle pattern2025 Retail Activity & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
LIXTE Biotechnology Targets Cancer Treatment Resistance with PP2A Inhibitor Platform - citybuzz -
Improving the Odds: How LIXTE Biotechnology (LIXT) Is Working to Make Cancer Therapies More Effective - NewMediaWire
Market Overview: What makes Lixte Biotechnology Holdings Inc. Equity Warrant stock attractive todayJuly 2025 Breakouts & Safe Capital Growth Plans - baoquankhu1.vn
Retail Trends: Is Lixte Biotechnology Holdings Inc a stock for growth or value investors2025 Analyst Calls & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
LIXTE Biotechnology Holdings (LIXT) Advances a Novel Approach to Enhancing Cancer Therapy - NewMediaWire
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event - The Globe and Mail
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Advances a Novel Approach to Enhancing Cancer Therapy - Digital Journal
Datavault AI (NASDAQ: DVLT) Closes Acquisition of API Media Innovation - financial-news.co.uk
De La Soul Set to Lead Good Health Summit at Morehouse College - EBONY Magazine
Stop Loss: Can C3is Inc weather a recessionEarnings Overview Summary & Safe Capital Growth Plans - baoquankhu1.vn
LIXTE Biotechnology Advances Novel Cancer Therapy Approach Targeting PP2A Enzyme - citybuzz -
Spartan Capital Securities, LLC Proudly Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $4.3 Million Registered Direct Offering - Big News Network.com
Highs Report: What makes Lixte Biotechnology Holdings Inc Equity Warrant stock attractive today2025 Growth vs Value & AI Powered Market Entry Ideas - baoquankhu1.vn
Is Lixte Biotechnology Holdings Inc stock a value trapFed Meeting & AI Forecasted Entry and Exit Points - baoquankhu1.vn
LIXTE Biotechnology Holdings (LIXT) Sponsors Good Health Mind, Body and Soul Summit - Yahoo Finance
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Sponsors Good Health Mind, Body and Soul Summit - Digital Journal
LIXTE Biotechnology Sponsors Health Equity Summit at Morehouse College, Linking Cancer Research to Community Wellness - citybuzz -
De La Soul's 'Good Health' summit targets Black men's wellness - Stock Titan
DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE - The Globe and Mail
Lixte Biotechnology to Present at DealFlow Discovery Conference as Clinical Trials Advance - citybuzz -
LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29 - manilatimes.net
How Lixte Biotechnology Holdings Inc. stock compares to growth peersSector Performance Review & Rapid Portfolio Trading - Bollywood Helpline
Is Lixte Biotechnology Holdings Inc. a stock for growth or value investorsQuarterly Earnings Summary & Real-Time Volume Trigger Notifications - bollywoodhelpline.com
Breakout Move: Can Arvinas Inc grow without external fundingJuly 2025 Spike Watch & Precise Buy Zone Identification - baoquankhu1.vn
Aug Movers: Is OPAD a play on infrastructure spending2025 Trade Ideas & Expert Approved Trade Ideas - baoquankhu1.vn
Pullback Watch: Whats the profit margin of Lixte Biotechnology Holdings IncJuly 2025 Action & Growth Oriented Trading Recommendations - baoquankhu1.vn
Institution Moves: How Lixte Biotechnology Holdings Inc stock performs after earningsJuly 2025 Market Mood & Low Volatility Stock Suggestions - Bộ Nội Vụ
LIXTE Biotechnology Engages IBN to Amplify Communications for Cancer Therapy Development - citybuzz -
About Us - FinancialContent
LIXTE Biotechnology (LIXT) Enhances Visibility with New Communications Strategy - GuruFocus
IBN Initiates Coverage of LIXTE Biotechnology Holdings Inc. - The Manila Times
Breakout Zone: Can Lixte Biotechnology Holdings Inc Equity Warrant withstand a market correctionPortfolio Gains Summary & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Weekly Trades: How Lixte Biotechnology Holdings Inc stock compares to growth peersEarnings Performance Report & Real-Time Buy Signal Notifications - Bộ Nội Vụ
Is Lixte Biotechnology Holdings Inc. stock trading at a premium valuationTreasury Yields & Expert-Curated Trade Recommendations - ulpravda.ru
Will Lixte Biotechnology Holdings Inc. stock see insider buyingTake Profit & Smart Swing Trading Techniques - Улправда
Is Lixte Biotechnology Holdings Inc. stock a buy before product launchesPortfolio Return Summary & Entry and Exit Point Strategies - ulpravda.ru
Should I hold or sell Lixte Biotechnology Holdings Inc. stock in 2025Weekly Investment Summary & Accurate Technical Buy Alerts - Улправда
Can Lixte Biotechnology Holdings Inc. (8640) stock ride next bull market cycleQuarterly Market Review & Technical Buy Zone Confirmation - Улправда
LIXTE Biotechnology Holdings (LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK - NewMediaWire
Will Lixte Biotechnology Holdings Inc. (8640) stock beat revenue estimatesFed Meeting & Low Risk Entry Point Tips - Улправда
Lixte Biotechnology Holdings Inc Stock (LIXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):